camrelizumab + capecitabine + pembrolizumab + sintilimab + tislelizumab + toripalimab

This is an experimental multi-agent combination therapy consisting of six drugs: five anti-PD‑1 monoclonal antibodies—camrelizumab, pembrolizumab, sintilimab, tislelizumab, and toripalimab—and the oral chemotherapeutic agent capecitabine. Each of the monoclonal antibodies targets programmed cell death protein 1 (PD‑1), blocking its interaction with PD-L1/PD-L2 to enhance T-cell mediated antitumor immunity. Capecitabine is a prodrug that is enzymatically converted to fluorouracil in tumor tissue, inhibiting DNA synthesis and slowing tumor growth. This specific six-drug regimen does not correspond to any approved or widely studied clinical protocol; however, various pairwise or triplet combinations among these agents have been investigated in solid tumors such as gastric cancer, esophageal cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, and others[3][4][5][6][7]. The rationale for combining multiple PD‑1 inhibitors with chemotherapy would be to maximize immune checkpoint blockade alongside cytotoxic effects; however, there are no known studies or approvals for using all five PD‑1 inhibitors together with capecitabine.

Brand names

Xeloda (capecitabine)Keytruda (pembrolizumab)